Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye
Abstract
:1. Introduction
2. Polymeric Nanoparticles
2.1. Natural Materials
2.1.1. Chitosan
2.1.2. Alginate
2.1.3. Other Natural Polymers
2.2. Synthetic Materials
2.2.1. Eudragit
2.2.2. PLGA
2.2.3. PLA
3. Polymeric Nanomicelles
4. Inorganic Particles
4.1. Gold Nanoparticles
4.2. Silver Nanoparticles
4.3. Cerium Particles (CeO2)
4.4. Silica Nanoparticles
4.5. Particles Formed by Inorganic Salts
5. In Situ Hydrogels as an Additional Carrier of Drug-Loaded Nanoparticles
6. Potential Ocular Nanomedicine
7. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
PLGA | poly(D,L-lactide-co-glycolide) |
PCL | poly(ε-caprolactone) |
PCA | polycyanoacrylate |
PEG | polyethylene glycol |
PVP | polyvinylpyrrolidone |
AUC | area under the pharmacokinetic curve |
IOP | intraocular pressure |
PVA | polyvinyl alcohol |
PLA | poly(lactide) |
PVCL | polyvinyl caprolactam |
PEO | poly(ethylene oxide) |
Pluronic | (poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide)) |
5-FU | 5-fluorouracil |
SOD | superoxide dismutase |
ROS | reactive oxygen species |
LCST | lower critical solution temperature |
References
- World Health Organization. Available online: https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment (accessed on 15 November 2021).
- Grassiri, B.; Zambito, Y.; Bernkop-Schnürch, A. Strategies to prolong the residence time of drug delivery systems on ocular surface. Adv. Colloid Interface Sci. 2021, 288, 102342. [Google Scholar] [CrossRef]
- Ghate, D.; Edelhauser, H.F. Ocular drug delivery. Expert Opin. Drug Deliv. 2006, 3, 275–287. [Google Scholar] [CrossRef]
- Gaudana, R.; Jwala, J.; Boddu, S.H.S.; Mitra, A.K. Recent perspectives in ocular drug delivery. Pharm. Res. 2009, 26, 1197–1216. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Patel, A.; Cholkar, K.; Agrahari, V.; Mitra, A.K. Ocular drug delivery systems: An overview. World J. Pharmacol. 2013, 2, 47. [Google Scholar] [CrossRef]
- Awwad, S.; Ahmed, A.H.A.M.; Sharma, G.; Heng, J.S.; Khaw, P.T.; Brocchini, S.; Lockwood, A. Principles of pharmacology in the eye. Br. J. Pharmacol. 2017, 174, 4205–4223. [Google Scholar] [CrossRef] [PubMed]
- Subrizi, A.; del Amo, E.M.; Korzhikov-Vlakh, V.; Tennikova, T.; Ruponen, M.; Urtti, A. Design principles of ocular drug delivery systems: Importance of drug payload, release rate, and material properties. Drug Discov. Today 2019, 24, 1446–1457. [Google Scholar] [CrossRef]
- Jumelle, C.; Gholizadeh, S.; Annabi, N.; Dana, R. Advances and limitations of drug delivery systems formulated as eye drops. J. Control. Release 2020, 321, 1–22. [Google Scholar] [CrossRef] [PubMed]
- Kompella, U.B.; Kadam, R.S.; Lee, V.H. Recent advances in ophthalmic drug delivery. Ther. Deliv. 2010, 1, 435–456. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Agrahari, V.; Mandal, A.; Agrahari, V.; Trinh, H.M.; Joseph, M.; Ray, A.; Hadji, H.; Mitra, R.; Pal, D.; Mitra, A.K. A comprehensive insight on ocular pharmacokinetics. Drug Deliv. Transl. Res. 2016, 6, 735–754. [Google Scholar] [CrossRef] [PubMed]
- Achouri, D.; Alhanout, K.; Piccerelle, P.; Andrieu, V. Recent advances in ocular drug delivery. Drug Dev. Ind. Pharm. 2013, 39, 1599–1617. [Google Scholar] [CrossRef]
- Kamaleddin, M.A. Nano-ophthalmology: Applications and considerations. Nanomed. Nanotechnol. Biol. Med. 2017, 13, 1459–1472. [Google Scholar] [CrossRef] [PubMed]
- Imperiale, J.C.; Acosta, G.B.; Sosnik, A. Polymer-based carriers for ophthalmic drug delivery. J. Control. Release 2018, 285, 106–141. [Google Scholar] [CrossRef] [PubMed]
- Watsky, M.A.; Jablonski, M.M.; Edelhauser, H.F. Comparison of conjunctival and corneal surface areas in rabbit and human. Curr. Eye Res. 1988, 7, 483–486. [Google Scholar] [CrossRef]
- Ramsay, E.; Ruponen, M.; Picardat, T.; Tengvall, U.; Tuomainen, M.; Auriola, S.; Toropainen, E.; Urtti, A.; del Amo, E.M. Impact of chemical structure on conjunctival drug permeability: Adopting porcine conjunctiva and cassette dosing for construction of in silico model. J. Pharm. Sci. 2017, 106, 2463–2471. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ahmed, I.; Gokhale, R.D.; Shah, M.V.; Patton, T.F. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J. Pharm. Sci. 1987, 76, 583–586. [Google Scholar] [CrossRef]
- Farkouh, A.; Frigo, P.; Czejka, M. Systemic side effects of eye drops: A pharmacokinetic perspective. Clin. Ophthalmol. 2016, 10, 2433–2441. [Google Scholar] [CrossRef] [Green Version]
- Mun, E.A.; Morrison, P.W.J.; Williams, A.C.; Khutoryanskiy, V.V. On the barrier properties of the cornea: A microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein. Mol. Pharm. 2014, 11, 3556–3564. [Google Scholar] [CrossRef]
- Dastjerdi, M.H.; Sadrai, Z.; Saban, D.R.; Zhang, Q.; Dana, R. Corneal penetration of topical and subconjunctival bevacizumab. Investig. Ophthalmol. Vis. Sci. 2011, 52, 8718–8723. [Google Scholar] [CrossRef] [Green Version]
- Morrison, P.W.; Khutoryanskiy, V. Advances in ophthalmic drug delivery. Ther. Deliv. 2014, 5, 1297–1315. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, T.; Xiang, C.D.; Gale, D.; Carreiro, S.; Wu, E.Y.; Zhang, E.Y. Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: Implications for ocular drug disposition. Drug Metab. Dispos. 2008, 36, 1300–1307. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Karla, P.K.; Earla, R.; Boddu, S.H.; Johnston, T.P.; Pal, D.; Mitra, A. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Curr. Eye Res. 2009, 34, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kölln, C.; Reichl, S. mRNA expression of metabolic enzymes in human cornea, corneal cell lines, and hemicornea constructs. J. Ocul. Pharmacol. Ther. 2012, 28, 271–277. [Google Scholar] [CrossRef] [Green Version]
- Srinivasarao, D.A.; Lohiya, G.; Katti, D.S. Fundamentals, challenges, and nanomedicine-based solutions for ocular diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2019, 11, e1548. [Google Scholar] [CrossRef] [PubMed]
- Zhang, S.; Gao, H.; Bao, G. Physical principles of nanoparticle cellular endocytosis. ACS Nano 2015, 9, 8655–8671. [Google Scholar] [CrossRef] [Green Version]
- Navarro-Partida, J.; Castro-Castaneda, C.R.; Cruz-Pavlovich, F.J.S.; Aceves-Franco, L.A.; Guy, T.O.; Santos, A. Lipid-based nanocarriers as topical drug delivery systems for intraocular diseases. Pharmaceutics 2021, 13, 678. [Google Scholar] [CrossRef]
- Janagam, D.R.; Wu, L.; Lowe, T.L. Nanoparticles for drug delivery to the anterior segment of the eye. Adv. Drug Deliv. Rev. 2017, 122, 31–64. [Google Scholar] [CrossRef]
- Bachu, R.D.; Chowdhury, P.; Al-Saedi, Z.H.F.; Karla, P.K.; Boddu, S.H.S. Ocular drug delivery barriers—Role of nanocarriers in the treatment of anterior segment ocular diseases. Pharmaceutics 2018, 10, 28. [Google Scholar] [CrossRef] [Green Version]
- Lakhani, P.; Patil, A.; Majumdar, S. Recent advances in topical nano drug-delivery systems for the anterior ocular segment. Ther. Deliv. 2018, 9, 137–153. [Google Scholar] [CrossRef] [PubMed]
- Mazet, R.; Yaméogo, J.B.G.; Wouessidjewe, D.; Choisnard, L.; Gèze, A. Recent advances in the design of topical ophthalmic delivery systems in the treatment of ocular surface inflammation and their biopharmaceutical evaluation. Pharmaceutics 2020, 12, 570. [Google Scholar] [CrossRef]
- Mobaraki, M.; Soltani, M.; Harofte, S.Z.; Zoudani, E.L.; Daliri, R.; Aghamirsalim, M.; Raahemifar, K. Biodegradable nanoparticle for cornea drug delivery: Focus review. Pharmaceutics 2020, 12, 1232. [Google Scholar] [CrossRef]
- Begines, B.; Ortiz, T.; Pérez-Aranda, M.; Martínez, G.; Merinero, M.; Argüelles-Arias, F.; Alcudia, A. Polymeric nanoparticles for drug delivery: Recent developments and future prospects. Nanomaterials 2020, 10, 1403. [Google Scholar] [CrossRef]
- Nagarwal, R.C.; Kant, S.; Singh, P.N.N.; Maiti, P.; Pandit, J.K.K. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J. Control. Release 2009, 136, 2–13. [Google Scholar] [CrossRef]
- Lynch, C.; Kondiah, P.P.D.; Choonara, Y.E.; du Toit, L.C.; Ally, N.; Pillay, V. Advances in biodegradable nano-sized polymer-based ocular drug delivery. Polymers 2019, 11, 1371. [Google Scholar] [CrossRef] [Green Version]
- Gorantla, S.; Rapalli, V.K.; Waghule, T.; Singh, P.P.; Dubey, S.K.; Saha, R.N.; Singhvi, G. Nanocarriers for ocular drug delivery: Current status and translational opportunity. RSC Adv. 2020, 10, 27835–27855. [Google Scholar] [CrossRef]
- Tsai, C.-H.; Wang, P.-Y.; Lin, I.-C.; Huang, H.; Liu, G.-S.; Tseng, C.-L. Ocular drug delivery: Role of degradable polymeric nanocarriers for ophthalmic application. Int. J. Mol. Sci. 2018, 19, 2830. [Google Scholar] [CrossRef] [Green Version]
- Losa, C.; Calvo, P.; Castro, E.; Vila-Jato, J.L.; Alonso, M.J. Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles. J. Pharm. Pharmacol. 2011, 43, 548–552. [Google Scholar] [CrossRef] [PubMed]
- Marchal-Heussler, L.; Maincent, P.; Hoffman, M.; Spittler, J.; Couvreur, P. Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutylcyanoacrylate nanoparticle preparations. Int. J. Pharm. 1990, 58, 115–122. [Google Scholar] [CrossRef]
- Müller, R.H.; Lherm, C.; Herbert, J.; Couvreur, P. In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials 1990, 11, 590–595. [Google Scholar] [CrossRef]
- Pignatello, R.; Bucolo, C.; Spedalieri, G.; Maltese, A.; Puglisi, G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002, 23, 3247–3255. [Google Scholar] [CrossRef]
- Giannavola, C.; Bucolo, C.; Maltese, A.; Paolino, D.; Vandelli, M.A.; Puglisi, G.; Lee, V.H.L.; Fresta, M. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm. Res. 2003, 20, 584–590. [Google Scholar] [CrossRef]
- Zhang, X.; Wei, D.; Xu, Y.; Zhu, Q. Hyaluronic acid in ocular drug delivery. Carbohydr. Polym. 2021, 264, 118006. [Google Scholar] [CrossRef]
- Zhao, R.; Li, J.; Wang, J.; Yin, Z.; Zhu, Y.; Liu, W. Development of timolol-loaded galactosylated chitosan nanoparticles and evaluation of their potential for ocular drug delivery. AAPS PharmSciTech 2017, 18, 997–1008. [Google Scholar] [CrossRef]
- Ameeduzzafar; Ali, J.; Bhatnagar, A.; Kumar, N.; Ali, A. Chitosan nanoparticles amplify the ocular hypotensive effect of cateolol in rabbits. Int. J. Biol. Macromol. 2014, 65, 479–491. [Google Scholar] [CrossRef] [PubMed]
- Shahab, M.S.; Rizwanullah, M.; Alshehri, S.; Imam, S.S. Optimization to development of chitosan decorated polycaprolactone nanoparticles for improved ocular delivery of dorzolamide: In vitro, ex vivo and toxicity assessments. Int. J. Biol. Macromol. 2020, 163, 2392–2404. [Google Scholar] [CrossRef]
- Kapanigowda, U.G.; Nagaraja, S.H.; Ramaiah, B.; Boggarapu, P.R. Improved intraocular bioavailability of ganciclovir by mucoadhesive polymer based ocular microspheres: Development and simulation process in Wistar rats. DARU J. Pharm. Sci. 2015, 23, 49. [Google Scholar] [CrossRef] [Green Version]
- Başaran, E.; Yenilmez, E.; Berkman, M.S.; Büyükköroğlu, G.; Yazan, Y. Chitosan nanoparticles for ocular delivery of cyclosporine A. J. Microencapsul. 2014, 31, 49–57. [Google Scholar] [CrossRef] [PubMed]
- Silva, N.C.; Silva, S.; Sarmento, B.; Pintado, M. Chitosan nanoparticles for daptomycin delivery in ocular treatment of bacterial endophthalmitis. Drug Deliv. 2015, 22, 885–893. [Google Scholar] [CrossRef] [Green Version]
- Alqahtani, F.Y.; Aleanizy, F.S.; El Tahir, E.; Alquadeib, B.T.; Alsarra, I.A.; Alanazi, J.S.; Abdelhady, H.G. Preparation, characterization, and antibacterial activity of diclofenac-loaded chitosan nanoparticles. Saudi Pharm. J. 2019, 27, 82–87. [Google Scholar] [CrossRef]
- Asasutjarit, R.; Theerachayanan, T.; Kewsuwan, P.; Veeranodha, S.; Fuongfuchat, A.; Ritthidej, G.C. Development and evaluation of diclofenac sodium loaded-n-trimethyl chitosan nanoparticles for ophthalmic use. AAPS PharmSciTech 2015, 16, 1013–1024. [Google Scholar] [CrossRef] [Green Version]
- Yu, A.; Shi, H.; Liu, H.; Bao, Z.; Dai, M.; Lin, D.; Lin, D.; Xu, X.; Li, X.; Wang, Y. Mucoadhesive dexamethasone-glycol chitosan nanoparticles for ophthalmic drug delivery. Int. J. Pharm. 2020, 575, 118943. [Google Scholar] [CrossRef] [PubMed]
- da Silva, S.B.; Ferreira, D.; Pintado, M.; Sarmento, B. Chitosan-based nanoparticles for rosmarinic acid ocular delivery-In vitro tests. Int. J. Biol. Macromol. 2016, 84, 112–120. [Google Scholar] [CrossRef] [PubMed]
- Shinde, U.A.; Shete, J.N.; Nair, H.A.; Singh, K.H. Design and characterization of chitosan-alginate microspheres for ocular delivery of azelastine. Pharm. Dev. Technol. 2014, 19, 813–823. [Google Scholar] [CrossRef] [PubMed]
- Nagarwal, R.C.; Kumar, R.; Pandit, J.K. Chitosan coated sodium alginate–chitosan nanoparticles loaded with 5-FU for ocular delivery: In vitro characterization and in vivo study in rabbit eye. Eur. J. Pharm. Sci. 2012, 47, 678–685. [Google Scholar] [CrossRef]
- Ibrahim, M.M.; Abd-Elgawad, A.-E.H.; Soliman, O.A.-E.; Jablonski, M.M. Natural bioadhesive biodegradable nanoparticle-based topical ophthalmic formulations for management of glaucoma. Transl. Vis. Sci. Technol. 2015, 4, 12. [Google Scholar] [CrossRef] [Green Version]
- Ali Attia Shafie, M. Formulation and evaluation of betamethasone sodium phosphate loaded nanoparticles for ophthalmic delivery. J. Clin. Exp. Ophthalmol. 2013, 4, 2. [Google Scholar] [CrossRef]
- Kimna, C.; Winkeljann, B.; Hoffmeister, J.; Lieleg, O. Biopolymer-based nanoparticles with tunable mucoadhesivity efficiently deliver therapeutics across the corneal barrier. Mater. Sci. Eng. C 2021, 121, 111890. [Google Scholar] [CrossRef] [PubMed]
- Addo, R.T.; Yeboah, K.G.; Siwale, R.C.; Siddig, A.; Jones, A.; Ubale, R.V.; Akande, J.; Nettey, H.; Patel, N.J.; Addo, E.; et al. Formulation and characterization of atropine sulfate in albumin-chitosan microparticles for in vivo ocular drug delivery. J. Pharm. Sci. 2015, 104, 1677–1690. [Google Scholar] [CrossRef]
- Natesan, S.; Pandian, S.; Ponnusamy, C.; Palanichamy, R.; Muthusamy, S.; Kandasamy, R. Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction. Int. J. Biol. Macromol. 2017, 104, 1837–1845. [Google Scholar] [CrossRef]
- Tseng, C.-L.; Chen, K.-H.; Su, W.-Y.; Lee, Y.-H.; Wu, C.-C.; Lin, F.-H. Cationic gelatin nanoparticles for drug delivery to the ocular surface: In Vitro and In Vivo evaluation. J. Nanomater. 2013, 2013, 238351. [Google Scholar] [CrossRef] [Green Version]
- Mahor, A.; Prajapati, S.K.; Verma, A.; Gupta, R.; Iyer, A.K.; Kesharwani, P. Moxifloxacin loaded gelatin nanoparticles for ocular delivery: Formulation and in-vitro, in-vivo evaluation. J. Colloid Interface Sci. 2016, 483, 132–138. [Google Scholar] [CrossRef]
- Konat Zorzi, G.; Contreras-Ruiz, L.; Párraga, J.E.; López-García, A.; Romero Bello, R.; Diebold, Y.; Seijo, B.; Sánchez, A. Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles. Mol. Pharm. 2011, 8, 1783–1788. [Google Scholar] [CrossRef]
- Katara, R.; Majumdar, D.K. Eudragit RL 100-based nanoparticulate system of aceclofenac for ocular delivery. Colloids Surf. B Biointerfaces 2013, 103, 455–462. [Google Scholar] [CrossRef]
- Katara, R.; Sachdeva, S.; Majumdar, D.K. Design, characterization, and evaluation of aceclofenac-loaded Eudragit RS 100 nanoparticulate system for ocular delivery. Pharm. Dev. Technol. 2019, 24, 368–379. [Google Scholar] [CrossRef]
- Verma, P.; Gupta, R.N.; Jha, A.K.; Pandey, R. Development, in vitro and in vivo characterization of Eudragit RL 100 nanoparticles for improved ocular bioavailability of acetazolamide. Drug Deliv. 2013, 20, 269–276. [Google Scholar] [CrossRef] [Green Version]
- Castro, B.F.M.; Fulgêncio, G.d.O.; Domingos, L.C.; Cotta, O.A.L.; Silva-Cunha, A.; Fialho, S.L. Positively charged polymeric nanoparticles improve ocular penetration of tacrolimus after topical administration. J. Drug Deliv. Sci. Technol. 2020, 60, 101912. [Google Scholar] [CrossRef]
- Gonzalez-Pizarro, R.; Silva-Abreu, M.; Calpena, A.C.; Egea, M.A.; Espina, M.; García, M.L. Development of fluorometholone-loaded PLGA nanoparticles for treatment of inflammatory disorders of anterior and posterior segments of the eye. Int. J. Pharm. 2018, 547, 338–346. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Katara, R.; Sachdeva, S.; Majumdar, D.K. Enhancement of ocular efficacy of aceclofenac using biodegradable PLGA nanoparticles: Formulation and characterization. Drug Deliv. Transl. Res. 2017, 7, 632–641. [Google Scholar] [CrossRef]
- Kalam, M.A.; Alshamsan, A. Poly (d, l-lactide-co-glycolide) nanoparticles for sustained release of tacrolimus in rabbit eyes. Biomed. Pharmacother. 2017, 94, 402–411. [Google Scholar] [CrossRef]
- Rebibo, L.; Tam, C.; Sun, Y.; Shoshani, E.; Badihi, A.; Nassar, T.; Benita, S. Topical tacrolimus nanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models. J. Control. Release 2021, 333, 283–297. [Google Scholar] [CrossRef]
- Cañadas, C.; Alvarado, H.; Calpena, A.C.; Silva, A.M.; Souto, E.B.; García, M.L.; Abrego, G. In vitro, ex vivo and in vivo characterization of PLGA nanoparticles loading pranoprofen for ocular administration. Int. J. Pharm. 2016, 511, 719–727. [Google Scholar] [CrossRef]
- Ghosh, A.K.; Thapa, R.; Hariani, H.N.; Volyanyuk, M.; Ogle, S.D.; Orloff, K.A.; Ankireddy, S.; Lai, K.; Žiniauskaitė, A.; Stubbs, E.B.; et al. Poly(lactic-co-glycolic acid) nanoparticles encapsulating the prenylated flavonoid, xanthohumol, protect corneal epithelial cells from dry eye disease-associated oxidative stress. Pharmaceutics 2021, 13, 1362. [Google Scholar] [CrossRef]
- Park, C.G.; Kim, Y.K.; Kim, S.-N.; Lee, S.H.; Huh, B.K.; Park, M.-A.; Won, H.; Park, K.H.; Choy, Y. Bin Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles. Int. J. Pharm. 2017, 522, 66–73. [Google Scholar] [CrossRef] [PubMed]
- Sánchez-López, E.; Egea, M.A.; Cano, A.; Espina, M.; Calpena, A.C.; Ettcheto, M.; Camins, A.; Souto, E.B.; Silva, A.M.; García, M.L. PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen—in vitro, ex vivo and in vivo characterization. Colloids Surf. B Biointerfaces 2016, 145, 241–250. [Google Scholar] [CrossRef] [Green Version]
- Sharma, A.K.; Sahoo, P.K.; Majumdar, D.K.; Panda, A.K. Topical ocular delivery of a COX-II inhibitor via biodegradable nanoparticles. Nanotechnol. Rev. 2016, 5, 435–444. [Google Scholar] [CrossRef]
- Yingfang, F.; Zhuang, B.; Wang, C.; Xu, X.; Xu, W.; Lv, Z. Pimecrolimus micelle exhibits excellent therapeutic effect for Keratoconjunctivitis Sicca. Colloids Surf. B Biointerfaces 2016, 140, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Yu, Y.; Chen, D.; Li, Y.; Yang, W.; Tu, J.; Shen, Y. Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: Formulation, in vitro and in vivo studies. Drug Deliv. 2018, 25, 888–899. [Google Scholar] [CrossRef] [Green Version]
- Sun, F.; Zheng, Z.; Lan, J.; Li, X.; Li, M.; Song, K.; Wu, X. New micelle myricetin formulation for ocular delivery: Improved stability, solubility, and ocular anti-inflammatory treatment. Drug Deliv. 2019, 26, 575–585. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shi, S.; Peng, F.; Zheng, Q.; Zeng, L.; Chen, H.; Li, X.; Huang, J. Micelle-solubilized axitinib for ocular administration in anti-neovascularization. Int. J. Pharm. 2019, 560, 19–26. [Google Scholar] [CrossRef]
- Alami-Milani, M.; Zakeri-Milani, P.; Valizadeh, H.; Sattari, S.; Salatin, S.; Jelvehgari, M. Evaluation of anti-inflammatory impact of dexamethasone-loaded PCL-PEG-PCL micelles on endotoxin-induced uveitis in rabbits. Pharm. Dev. Technol. 2019, 24, 680–688. [Google Scholar] [CrossRef]
- Kost, O.A.; Beznos, O.V.; Davydova, N.G.; Manickam, D.S.; Nikolskaya, I.I.; Guller, A.E.; Binevski, P.V.; Chesnokova, N.B.; Shekhter, A.B.; Klyachko, N.L.; et al. Superoxide Dismutase 1 nanozyme for treatment of eye inflammation. Oxid. Med. Cell. Longev. 2016, 2016, 5194239. [Google Scholar] [CrossRef] [Green Version]
- Vaneev, A.N.; Kost, O.A.; Eremeev, N.L.; Beznos, O.V.; Alova, A.V.; Gorelkin, P.V.; Erofeev, A.S.; Chesnokova, N.B.; Kabanov, A.V.; Klyachko, N.L. Superoxide Dismutase 1 Nanoparticles (Nano-SOD1) as a potential drug for the treatment of inflammatory eye diseases. Biomedicines 2021, 9, 396. [Google Scholar] [CrossRef]
- Salama, A.H.; Shamma, R.N. Tri/tetra-block co-polymeric nanocarriers as a potential ocular delivery system of lornoxicam: In-vitro characterization, and in-vivo estimation of corneal permeation. Int. J. Pharm. 2015, 492, 28–39. [Google Scholar] [CrossRef] [PubMed]
- Rabinovich-Guilatt, L.; Couvreur, P.; Lambert, G.; Dubernet, C. Cationic vectors in ocular drug delivery. J. Drug Target. 2004, 12, 623–633. [Google Scholar] [CrossRef] [PubMed]
- Ways, T.M.M.; Lau, W.M.; Khutoryanskiy, V.V. Chitosan and its derivatives for application in mucoadhesive drug delivery systems. Polymers 2018, 10, 267. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sogias, I.A.; Williams, A.C.; Khutoryanskiy, V.V. Why is Chitosan Mucoadhesive? Biomacromolecules 2008, 9, 1837–1842. [Google Scholar] [CrossRef]
- Khan, N.; Ameeduzzafar; Khanna, K.; Bhatnagar, A.; Ahmad, F.J.; Ali, A. Chitosan coated PLGA nanoparticles amplify the ocular hypotensive effect of forskolin: Statistical design, characterization and in vivo studies. Int. J. Biol. Macromol. 2018, 116, 648–663. [Google Scholar] [CrossRef]
- Sawtarie, N.; Cai, Y.; Lapitsky, Y. Preparation of chitosan/tripolyphosphate nanoparticles with highly tunable size and low polydispersity. Colloids Surf. B Biointerfaces 2017, 157, 110–117. [Google Scholar] [CrossRef]
- Zafar, A.; Alruwaili, N.K.; Imam, S.S.; Alsaidan, O.A.; Alharbi, K.S.; Yasir, M.; Elmowafy, M.; Ansari, M.J.; Salahuddin, M.; Alshehri, S. Formulation of carteolol chitosomes for ocular delivery: Formulation optimization, ex-vivo permeation, and ocular toxicity examination. Cutan. Ocul. Toxicol. 2021, 338–349. [Google Scholar] [CrossRef]
- Badawi, A.A.; El-Laithy, H.M.; El Qidra, R.K.; El Mofty, H.; El dally, M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch. Pharm. Res. 2008, 31, 1040–1049. [Google Scholar] [CrossRef] [PubMed]
- Salama, A.H.; Mahmoud, A.A.; Kamel, R. A novel method for preparing surface-modified fluocinolone acetonide loaded plga nanoparticles for ocular use: In Vitro and In Vivo evaluations. AAPS PharmSciTech 2016, 17, 1159–1172. [Google Scholar] [CrossRef]
- Song, S.; Zhou, W.; Wang, Y.; Jian, J. Self-aggregated nanoparticles based on amphiphilic poly(lactic acid)-grafted-chitosan copolymer for ocular delivery of amphotericin B. Int. J. Nanomed. 2013, 8, 3715–3728. [Google Scholar] [CrossRef] [Green Version]
- Pandian, S.; Jeevanesan, V.; Ponnusamy, C.; Natesan, S. RES-loaded pegylated CS NPs: For efficient ocular delivery. IET Nanobiotechnol. 2017, 11, 32–39. [Google Scholar] [CrossRef]
- Giunchedi, P.; Chetoni, P.; Conte, U.; Saettone, M.F. Albumin microspheres for ocular delivery of piroxicam. Pharm. Pharmacol. Commun. 2000, 6, 149–153. [Google Scholar] [CrossRef]
- Addo, R.T.; Siddig, A.; Siwale, R.; Patel, N.J.; Akande, J.; Uddin, A.N.; D’Souza, M.J. Formulation, characterization and testing of tetracaine hydrochloride-loaded albumin-chitosan microparticles for ocular drug delivery. J. Microencapsul. 2010, 27, 95–104. [Google Scholar] [CrossRef] [PubMed]
- Ahuja, M.; Dhake, A.S.; Sharma, S.K.; Majumdar, D.K. Diclofenac-loaded Eudragit S100 nanosuspension for ophthalmic delivery. J. Microencapsul. 2011, 28, 37–45. [Google Scholar] [CrossRef]
- Romeo, A.; Musumeci, T.; Carbone, C.; Bonaccorso, A.; Corvo, S.; Lupo, G.; Anfuso, C.D.; Puglisi, G.; Pignatello, R. Ferulic acid-loaded polymeric nanoparticles for potential ocular delivery. Pharmaceutics 2021, 13, 687. [Google Scholar] [CrossRef]
- Ding, D.; Kundukad, B.; Somasundar, A.; Vijayan, S.; Khan, S.A.; Doyle, P.S. Design of Mucoadhesive PLGA Microparticles for Ocular Drug Delivery. ACS Appl. Bio Mater. 2018, 1, 561–571. [Google Scholar] [CrossRef]
- Pandit, J.; Sultana, Y.; Aqil, M. Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: Optimization, characterization, and in vitro toxicity evaluation. Artif. Cells Nanomed. Biotechnol. 2017, 45, 1397–1407. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tyler, B.; Gullotti, D.; Mangraviti, A.; Utsuki, T.; Brem, H. Polylactic acid (PLA) controlled delivery carriers for biomedical applications. Adv. Drug Deliv. Rev. 2016, 107, 163–175. [Google Scholar] [CrossRef]
- Gentile, P.; Chiono, V.; Carmagnola, I.; Hatton, P. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int. J. Mol. Sci. 2014, 15, 3640–3659. [Google Scholar] [CrossRef]
- Liu, S.; Jones, L.; Gu, F.X. Development of mucoadhesive drug delivery system using phenylboronic acid functionalized poly(D, L-lactide)-b-dextran nanoparticles. Macromol. Biosci. 2012, 12, 1622–1626. [Google Scholar] [CrossRef] [PubMed]
- Mandal, A.; Bisht, R.; Rupenthal, I.D.; Mitra, A.K. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J. Control. Release 2017, 248, 96–116. [Google Scholar] [CrossRef] [Green Version]
- Deshmukh, A.S.; Chauhan, P.N.; Noolvi, M.N.; Chaturvedi, K.; Ganguly, K.; Shukla, S.S.; Nadagouda, M.N.; Aminabhavi, T.M. Polymeric micelles: Basic research to clinical practice. Int. J. Pharm. 2017, 532, 249–268. [Google Scholar] [CrossRef] [PubMed]
- Tawfik, S.M.; Azizov, S.; Elmasry, M.R.; Sharipov, M.; Lee, Y.-I. Recent advances in nanomicelles delivery systems. Nanomaterials 2020, 11, 70. [Google Scholar] [CrossRef] [PubMed]
- Grimaudo, M.A.; Pescina, S.; Padula, C.; Santi, P.; Concheiro, A.; Alvarez-Lorenzo, C.; Nicoli, S. Topical application of polymeric nanomicelles in ophthalmology: A review on research efforts for the noninvasive delivery of ocular therapeutics. Expert Opin. Drug Deliv. 2019, 16, 397–413. [Google Scholar] [CrossRef]
- Durgun, M.E.; Güngör, S.; Özsoy, Y. Micelles: Promising ocular drug carriers for anterior and posterior segment diseases. J. Ocul. Pharmacol. Ther. 2020, 36, 323–341. [Google Scholar] [CrossRef]
- Özsoy, Y.; Güngör, S.; Kahraman, E.; Durgun, M.E. Polymeric micelles as a novel carrier for ocular drug delivery. In Nanoarchitectonics in Biomedicine; Elsevier: Amsterdam, The Netherlands, 2019; pp. 85–117. [Google Scholar]
- Prosperi-Porta, G.; Kedzior, S.; Muirhead, B.; Sheardown, H. Phenylboronic-acid-based polymeric micelles for mucoadhesive anterior segment ocular drug delivery. Biomacromolecules 2016, 17, 1449–1457. [Google Scholar] [CrossRef]
- Masse, F.; Ouellette, M.; Lamoureux, G.; Boisselier, E. Gold nanoparticles in ophthalmology. Med. Res. Rev. 2019, 39, 302–327. [Google Scholar] [CrossRef] [Green Version]
- Apaolaza, P.S.; Busch, M.; Asin-Prieto, E.; Peynshaert, K.; Rathod, R.; Remaut, K.; Dünker, N.; Göpferich, A. Hyaluronic acid coating of gold nanoparticles for intraocular drug delivery: Evaluation of the surface properties and effect on their distribution. Exp. Eye Res. 2020, 198. [Google Scholar] [CrossRef]
- Masse, F.; Desjardins, P.; Ouellette, M.; Couture, C.; Omar, M.M.; Pernet, V.; Guérin, S.; Boisselier, E. Synthesis of ultrastable gold nanoparticles as a new drug delivery system. Molecules 2019, 24, 2929. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Salem, H.F.; Ahmed, S.M.; Omar, M.M. Liposomal flucytosine capped with gold nanoparticle formulations for improved ocular delivery. Drug Des. Devel. Ther. 2016, 10, 277–295. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pereira, D.V.; Petronilho, F.; Pereira, H.R.S.B.; Vuolo, F.; Mina, F.; Possato, J.C.; Vitto, M.F.; de Souza, D.R.; da Silva, L.; Paula, M.M.d.S.; et al. Effects of gold nanoparticles on endotoxin-induced uveitis in rats. Investig. Ophthalmol. Vis. Sci. 2012, 53, 8036–8041. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nguyen, D.D.; Luo, L.J.; Lai, J.Y. Toward understanding the purely geometric effects of silver nanoparticles on potential application as ocular therapeutics via treatment of bacterial keratitis. Mater. Sci. Eng. C 2021, 119, 111497. [Google Scholar] [CrossRef]
- Anbukkarasi, M.; Thomas, P.A.; Sheu, J.R.; Geraldine, P. In vitro antioxidant and anticataractogenic potential of silver nanoparticles biosynthesized using an ethanolic extract of Tabernaemontana divaricata leaves. Biomed. Pharmacother. 2017, 91, 467–475. [Google Scholar] [CrossRef] [PubMed]
- MacCarone, R.; Tisi, A.; Passacantando, M.; Ciancaglini, M. Ophthalmic applications of cerium oxide nanoparticles. J. Ocul. Pharmacol. Ther. 2020, 36, 376–383. [Google Scholar] [CrossRef] [PubMed]
- Khorrami, M.B.; Sadeghnia, H.R.; Pasdar, A.; Ghayour-Mobarhan, M.; Riahi-Zanjani, B.; Hashemzadeh, A.; Zare, M.; Darroudi, M. Antioxidant and toxicity studies of biosynthesized cerium oxide nanoparticles in rats. Int. J. Nanomed. 2019, 14, 2915–2926. [Google Scholar] [CrossRef] [Green Version]
- Chen, X.; Zhu, S.; Hu, X.; Sun, D.; Yang, J.; Yang, C.; Wu, W.; Li, Y.; Gu, X.; Li, M.; et al. Toxicity and mechanism of mesoporous silica nanoparticles in eyes. Nanoscale 2020, 12, 13637–13653. [Google Scholar] [CrossRef]
- Kim, S.N.; Ko, S.A.; Park, C.G.; Lee, S.H.; Huh, B.K.; Park, Y.H.; Kim, Y.K.; Ha, A.; Park, K.H.; Choy, Y. Bin Amino-functionalized mesoporous silica particles for ocular delivery of brimonidine. Mol. Pharm. 2018, 15, 3143–3152. [Google Scholar] [CrossRef] [PubMed]
- Nikolskaya, I.I.; Beznos, O.V.; Eltsov, A.I.; Gachok, I.V.; Chesnokova, N.B.; Varlamov, V.P.; Kost, O.A. The inclusion of timolol and lisinopril in calcium phosphate particles covered by chitosan: Application in ophthalmology. Vestn. Mosk. Univ. 2018, 59, 170–176. [Google Scholar] [CrossRef]
- Shimanovskaya, E.V.; Nikol’skaya, I.I.; Binevskii, P.V.; Klyachko, N.L.; Kost, O.A.; Beznos, O.V.; Pavlenko, T.A.; Chesnokova, N.B. Lisinopril in the composition of calcium phosphate nanoparticles as a promising antiglaucoma agent. Nanotechnol. Russ. 2014, 9, 219–226. [Google Scholar] [CrossRef]
- Binevski, P.V.; Balabushevich, N.G.; Uvarova, V.I.; Vikulina, A.S. Bio-friendly encapsulation of superoxide dismutase into vaterite CaCO3 crystals. Enzyme activity, release mechanism, and perspectives for ophthalmology. Colloids Surf. B Biointerfaces 2019, 181, 437–449. [Google Scholar] [CrossRef] [PubMed]
- Bruschi, M.L.; de Toledo, L.d.A.S. Pharmaceutical applications of iron-oxide magnetic nanoparticles. Magnetochemistry 2019, 5, 50. [Google Scholar] [CrossRef] [Green Version]
- Maulvi, F.A.; Patil, R.J.; Desai, A.R.; Shukla, M.R.; Vaidya, R.J.; Ranch, K.M.; Vyas, B.A.; Shah, S.A.; Shah, D.O. Effect of gold nanoparticles on timolol uptake and its release kinetics from contact lenses: In vitro and in vivo evaluation. Acta Biomater. 2019, 86, 350–362. [Google Scholar] [CrossRef]
- Karakoçak, B.B.; Raliya, R.; Davis, J.T.; Chavalmane, S.; Wang, W.N.; Ravi, N.; Biswas, P. Biocompatibility of gold nanoparticles in retinal pigment epithelial cell line. Toxicol. Vitr. 2016, 37, 61–69. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Xia, R.; Hu, H.; Peng, T. Biosynthesis, characterization and cytotoxicity of gold nanoparticles and their loading with N-acetylcarnosine for cataract treatment. J. Photochem. Photobiol. B Biol. 2018, 187, 180–183. [Google Scholar] [CrossRef]
- Li, Y.-J.; Luo, L.-J.; Harroun, S.G.; Wei, S.-C.; Unnikrishnan, B.; Chang, H.-T.; Huang, Y.-F.; Lai, J.-Y.; Huang, C.-C. Synergistically dual-functional nano eye-drops for simultaneous anti-inflammatory and anti-oxidative treatment of dry eye disease. Nanoscale 2019, 11, 5580–5594. [Google Scholar] [CrossRef]
- Hendiger, E.B.; Padzik, M.; Sifaoui, I.; Reyes-Batlle, M.; López-Arencibia, A.; Rizo-Liendo, A.; Bethencourt-Estrella, C.J.; Nicolás-Hernández, D.S.; Chiboub, O.; Rodríguez-Expósito, R.L.; et al. Silver nanoparticles as a novel potential preventive agent against acanthamoeba keratitis. Pathogens 2020, 9, 350. [Google Scholar] [CrossRef]
- Mathew, T.V.; Kuriakose, S. Photochemical and antimicrobial properties of silver nanoparticle-encapsulated chitosan functionalized with photoactive groups. Mater. Sci. Eng. C 2013, 33, 4409–4415. [Google Scholar] [CrossRef] [PubMed]
- Yang, T.; Yao, Q.; Cao, F.; Liu, Q.; Liu, B.; Wang, X.-H. Silver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: Insight into the cytotoxicity and antiangiogenesis. Int. J. Nanomed. 2016, 11, 6679–6692. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.J.; Wang, Z.Y.; Zhao, G.; Liu, J.X. Silver nanoparticles affect lens rather than retina development in zebrafish embryos. Ecotoxicol. Environ. Saf. 2018, 163, 279–288. [Google Scholar] [CrossRef]
- Kim, J.S.; Song, K.S.; Sung, J.H.; Ryu, H.R.; Choi, B.G.; Cho, H.S.; Lee, J.K.; Yu, I.J. Genotoxicity, acute oral and dermal toxicity, eye and dermal irritation and corrosion and skin sensitisation evaluation of silver nanoparticles. Nanotoxicology 2012, 7, 953–960. [Google Scholar] [CrossRef]
- Wong, L.L.; Hirst, S.M.; Pye, Q.N.; Reilly, C.M.; Seal, S.; McGinnis, J.F. Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection. PLoS ONE 2013, 8, e58431. [Google Scholar] [CrossRef]
- Baldim, V.; Yadav, N.; Bia, N.; Graillot, A.; Loubat, C.; Singh, S.; Karakoti, A.S.; Berret, J.-F. Polymer-coated cerium oxide nanoparticles as oxidoreductase-like catalysts. ACS Appl. Mater. Interfaces 2020, 12, 42056–42066. [Google Scholar] [CrossRef]
- Cai, X.; Seal, S.; McGinnis, J.F. Non-toxic retention of nanoceria in murine eyes. Mol. Vis. 2016, 22, 1176. [Google Scholar]
- Yu, F.; Zheng, M.; Zhang, A.Y.; Han, Z. A cerium oxide loaded glycol chitosan nano-system for the treatment of dry eye disease. J. Control. Release 2019, 315, 40. [Google Scholar] [CrossRef] [PubMed]
- Luo, L.J.; Nguyen, D.D.; Lai, J.Y. Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: A push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy. Biomaterials 2020, 243, 119961. [Google Scholar] [CrossRef] [PubMed]
- Trofimov, A.D.; Ivanova, A.A.; Zyuzin, M.V.; Timin, A.S. Porous inorganic carriers based on silica, calcium carbonate and calcium phosphate for controlled/modulated drug delivery: Fresh outlook and future perspectives. Pharmaceutics 2018, 10, 167. [Google Scholar] [CrossRef] [Green Version]
- Kim, J.-Y.; Park, J.-H.; Kim, M.; Jeong, H.; Hong, J.; Chuck, R.S.; Park, C.Y. Safety of nonporous silica nanoparticles in human corneal endothelial cells. Sci. Rep. 2017, 7, 14566. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Park, J.-H.; Jeong, H.; Hong, J.; Chang, M.; Kim, M.; Chuck, R.S.; Lee, J.K.; Park, C.-Y. The effect of silica nanoparticles on human corneal epithelial cells. Sci. Rep. 2016, 6, 37762. [Google Scholar] [CrossRef] [Green Version]
- Kim, M.; Park, J.H.; Jeong, H.; Hong, J.; Park, C.Y. Effects of nonporous silica nanoparticles on human trabecular meshwork cells. J. Glaucoma 2021, 30, 195–202. [Google Scholar] [CrossRef]
- Jo, D.H.; Kim, J.H.; Yu, Y.S.; Lee, T.G.; Kim, J.H. Antiangiogenic effect of silicate nanoparticle on retinal neovascularization induced by vascular endothelial growth factor. Nanomed. Nanotechnol. Biol. Med. 2012, 8, 784–791. [Google Scholar] [CrossRef]
- Sun, J.G.; Jiang, Q.; Zhang, X.P.; Shan, K.; Liu, B.H.; Zhao, C.; Yan, B. Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy. Int. J. Nanomed. 2019, 14, 1489–1501. [Google Scholar] [CrossRef] [Green Version]
- Liao, Y.-T.; Lee, C.-H.; Chen, S.-T.; Lai, J.-Y.; Wu, K.C.-W. Gelatin-functionalized mesoporous silica nanoparticles with sustained release properties for intracameral pharmacotherapy of glaucoma. J. Mater. Chem. B 2017, 5, 7008–7013. [Google Scholar] [CrossRef] [PubMed]
- Chen, R.; Qian, Y.; Li, R.; Zhang, Q.; Liu, D.; Wang, M.; Xu, Q. Methazolamide calcium phosphate nanoparticles in an ocular delivery system. Yakugaku Zasshi 2010, 130, 419–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Safi, S.; Karimzadeh, F.; Labbaf, S. Mesoporous and hollow hydroxyapatite nanostructured particles as a drug delivery vehicle for the local release of ibuprofen. Mater. Sci. Eng. C 2018, 92, 712–719. [Google Scholar] [CrossRef] [PubMed]
- Tolba, E.; Müller, W.E.G.; Abd El-Hady, B.M.; Neufurth, M.; Wurm, F.; Wang, S.; Schröder, H.C.; Wang, X. High biocompatibility and improved osteogenic potential of amorphous calcium carbonate/vaterite. J. Mater. Chem. B 2016, 4, 376–386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roth, R.; Schoelkopf, J.; Huwyler, J.; Puchkov, M. Functionalized calcium carbonate microparticles for the delivery of proteins. Eur. J. Pharm. Biopharm. 2018, 122, 96–103. [Google Scholar] [CrossRef]
- Chesnokova, N.B.; Nikolskaya, I.I.; Kost, O.A.; Beznos, O.V.; Galitskiy, V.A. Calcium phosphate particles containing superoxide dismutase are a promising agent for the treatment of eye diseases accompanied by oxidative stress. Moscow Univ. Chem. Bull. 2016, 71, 154–159. [Google Scholar] [CrossRef]
- Li, J.; Chen, Y.-C.C.; Tseng, Y.-C.C.; Mozumdar, S.; Huang, L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J. Control. Release 2010, 142, 416–421. [Google Scholar] [CrossRef] [Green Version]
- Guo, L.; Wang, L.; Yang, R.; Feng, R.; Li, Z.; Zhou, X.; Dong, Z.; Ghartey-Kwansah, G.; Xu, M.M.; Nishi, M.; et al. Optimizing conditions for calcium phosphate mediated transient transfection. Saudi J. Biol. Sci. 2017, 24, 622–629. [Google Scholar] [CrossRef]
- Trushina, D.B.; Bukreeva, T.V.; Kovalchuk, M.V.; Antipina, M.N. CaCO3 vaterite microparticles for biomedical and personal care applications. Mater. Sci. Eng. C 2014, 45, 644–658. [Google Scholar] [CrossRef]
- Balabushevich, N.G.; Kovalenko, E.A.; Mikhalchik, E.V.; Filatova, L.Y.; Volodkin, D.; Vikulina, A.S. Mucin adsorption on vaterite CaCO3 microcrystals for the prediction of mucoadhesive properties. J. Colloid Interface Sci. 2019, 545, 330–339. [Google Scholar] [CrossRef] [PubMed]
- Parakhonskiy, B.V.; Foss, C.; Carletti, E.; Fedel, M.; Haase, A.; Motta, A.; Migliaresi, C. Renzo antolini tailored intracellular delivery via a crystal phase transition in 400 nm vaterite particles. Biomater. Sci. 2013, 1, 1273–1281. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, Y.; Du, W.; Sun, L.; Yu, L.; Jiao, J.; Wang, R. Facile synthesis of calcium carbonate with an absolutely pure crystal form using 1-butyl-3-methylimidazolium dodecyl sulfate as the modifier. Colloid Polym. Sci. 2013, 291, 2191–2202. [Google Scholar] [CrossRef]
- Borodina, T.N.; Trushina, D.B.; Marchenko, I.V.; Bukreeva, T.V. Calcium carbonate-based mucoadhesive microcontainers for intranasal delivery of drugs bypassing the blood–brain barrier. Bionanoscience 2016, 6, 261–268. [Google Scholar] [CrossRef]
- Vikulina, A.S.; Feoktistova, N.A.; Balabushevich, N.G.; Skirtach, A.G.; Volodkin, D. The mechanism of catalase loading into porous vaterite CaCO3 crystals by co-synthesis. Phys. Chem. Chem. Phys. 2018, 20, 8822–8831. [Google Scholar] [CrossRef] [Green Version]
- Dorozhkin, S.V.; Epple, M. Biological and medical significance of calcium phosphates. Angew. Chemie Int. Ed. 2002, 41, 3130–3146. [Google Scholar] [CrossRef]
- Liu, Y.; Hunziker, E.B.; Randall, N.X.; de Groot, K.; Layrolle, P. Proteins incorporated into biomimetically prepared calcium phosphate coatings modulate their mechanical strength and dissolution rate. Biomaterials 2003, 24, 65–70. [Google Scholar] [CrossRef]
- Shimanovskaia, E.V.; Beznos, O.V.; Klyachko, N.L.; Kost, O.A.; Nikol’skaia, I.I.; Pavlenko, T.A.; Chesnokova, N.B.; Kabanov, A.V. Production of timolol containing calcium-phosphate nanoparticles and evaluation of their effect on intraocular pressure in experiment. Vestn Oftalmol. 2012, 128, 15–18. [Google Scholar]
- Morçöl, T.; Weidner, J.M.; Mehta, A.; Bell, S.J.D.; Block, T. Calcium phosphate particles as pulmonary delivery system for interferon-α in mice. AAPS PharmSciTech 2017, 19, 395–412. [Google Scholar] [CrossRef]
- Banik, M.; Basu, T. Calcium phosphate nanoparticles: A study of their synthesis, characterization and mode of interaction with salmon testis DNA. Dalt. Trans. 2014, 43, 3244–3259. [Google Scholar] [CrossRef]
- Qi, C.; Zhu, Y.; Zhao, X.; Lu, B.; Tang, Q.; Zhao, J. Highly stable amorphous calcium phosphate porous nanospheres: Microwave-assisted rapid synthesis using ATP as phosphorus source and stabilizer, and their application in anticancer drug delivery. Chem. Eur. J. 2013, 19, 981–987. [Google Scholar] [CrossRef]
- Sharma, R.; Barth, B.M.; Altino, E.İ.; Morgan, T.T.; Sriram, S.; Kaiser, J.M.; Mcgovern, C.; Matters, G.L.; Jill, P.; Kester, M.; et al. Bioconjugation of calcium phosphate nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano 2011, 4, 1279–1287. [Google Scholar] [CrossRef]
- Tang, J.; Li, L.; Howard, C.B.; Mahler, S.M.; Huang, L.; Xu, Z.P. Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene delivery to breast cancer cells. J. Mater. Chem. B 2015, 3, 6805–6812. [Google Scholar] [CrossRef]
- Singh, S.; Bhardwaj, P.; Singh, V.; Aggarwal, S.; Mandal, U.K. Synthesis of nanocrystalline calcium phosphate in microemulsion—effect of nature of surfactants. J. Colloid Interface Sci. 2008, 319, 322–329. [Google Scholar] [CrossRef]
- Severin, A.V.; Orlova, M.A.; Shalamova, E.S.; Egorov, A.V.; Sirotin, M.A. Nanohydroxyapatite and its textures as potential carriers of promising short-lived lead isotopes. Russ. Chem. Bull. 2019, 68, 2197–2204. [Google Scholar] [CrossRef]
- Agarwal, R.; Krasilnikova, A.V.; Raja, I.S.; Agarwal, P.; Ismail, N.M. Mechanisms of angiotensin converting enzyme inhibitor-induced IOP reduction in normotensive rats. Eur. J. Pharmacol. 2014, 730, 8–13. [Google Scholar] [CrossRef]
- Pitorre, M.; Gondé, H.; Haury, C.; Messous, M.; Poilane, J.; Boudaud, D.; Kanber, E.; Rossemond Ndombina, G.A.; Benoit, J.P.; Bastiat, G. Recent advances in nanocarrier-loaded gels: Which drug delivery technologies against which diseases? J. Control. Release 2017, 266, 140–155. [Google Scholar] [CrossRef] [PubMed]
- Upadhayay, P.; Kumar, M.; Pathak, K. Norfloxacin loaded pH triggered nanoparticulate in-situ gel for extraocular bacterial infections: Optimization, ocular irritancy and corneal toxicity. Iran. J. Pharm. Res. 2016, 15, 3–22. [Google Scholar] [CrossRef] [PubMed]
- Wu, Y.; Liu, Y.; Li, X.; Kebebe, D.; Zhang, B.; Ren, J.; Lu, J.; Li, J.; Du, S.; Liu, Z. Research progress of in-situ gelling ophthalmic drug delivery system. Asian J. Pharm. Sci. 2019, 14, 1–15. [Google Scholar] [CrossRef] [PubMed]
- Singh, J.; Chhabra, G.; Pathak, K. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: In vitro, ex vivo evaluation and pharmacodynamic study. Drug Dev. Ind. Pharm. 2014, 40, 1223–1232. [Google Scholar] [CrossRef]
- Agrawal, A.K.; Das, M.; Jain, S. In situ gel systems as “smart” carriers for sustained ocular drug delivery. Expert Opin. Drug Deliv. 2012, 9, 383–402. [Google Scholar] [CrossRef]
- Patil, P.R.; Shaikh, S.S.; Shivsharan, K.J.; Shahi, S.R. In situ: A novel drug delivery system. Indo Am. J. Pharm. Res. 2014, 4, 5406–5414. [Google Scholar]
- Deka, M.; Ahmed, A.B.; Chakraborty, J. Development, evaluation and characteristics of ophthalmic in situ gel system: A Review. Int. J. Curr. Pharm. Res. 2019, 11, 47–53. [Google Scholar] [CrossRef] [Green Version]
- Qian, Y.; Wang, F.; Li, R.; Zhang, Q.; Xu, Q. Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide. Drug Dev. Ind. Pharm. 2010, 36, 1340–1347. [Google Scholar] [CrossRef]
- Asasutjarit, R.; Thanasanchokpibull, S.; Fuongfuchat, A.; Veeranondha, S. Optimization and evaluation of thermoresponsive diclofenac sodium ophthalmic in situ gels. Int. J. Pharm. 2011, 411, 128–135. [Google Scholar] [CrossRef]
- Li, J.; Liu, H.; Liu, L.L.; Cai, C.N.; Xin, H.X.; Liu, W. Design and evaluation of a brinzolamide drug-resin in situ thermosensitive gelling system for sustained ophthalmic drug delivery. Chem. Pharm. Bull. 2014, 62, 1000–1008. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maddiboyina, B.; Jhawat, V.; Desu, P.K.; Gandhi, S.; Nakkala, R.K.; Singh, S. Formulation and evaluation of thermosensitive flurbiprofen in situ nano gel for the ocular delivery. J. Biomater. Sci. Polym. Ed. 2021, 32, 1584–1597. [Google Scholar] [CrossRef]
- Liu, R.; Sun, L.; Fang, S.; Wang, S.; Chen, J.; Xiao, X.; Liu, C. Thermosensitive in situ nanogel as ophthalmic delivery system of curcumin: Development, characterization, in vitro permeation and in vivo pharmacokinetic studies. Pharm. Dev. Technol. 2016, 21, 576–582. [Google Scholar] [CrossRef] [PubMed]
- Almeida, H.; Lobão, P.; Frigerio, C.; Fonseca, J.; Silva, R.; Sousa Lobo, J.M.; Amaral, M.H. Preparation, characterization and biocompatibility studies of thermoresponsive eyedrops based on the combination of nanostructured lipid carriers (NLC) and the polymer Pluronic F-127 for controlled delivery of ibuprofen. Pharm. Dev. Technol. 2017, 22, 336–349. [Google Scholar] [CrossRef]
- Shukr, M.H. Novel in situ gelling ocular inserts for voriconazole-loaded niosomes: Design, in vitro characterisation and in vivo evaluation of the ocular irritation and drug pharmacokinetics. J. Microencapsul. 2016, 33, 71–79. [Google Scholar] [CrossRef] [PubMed]
- Paradkar, M.U.; Parmar, M. Formulation development and evaluation of natamycin niosomal in-situ gel for ophthalmic drug delivery. J. Drug Deliv. Sci. Technol. 2017, 39, 113–122. [Google Scholar] [CrossRef]
- Obiedallah, M.M.; Abdel-Mageed, A.M.; Elfaham, T.H. Ocular administration of acetazolamide microsponges in situ gel formulations. Saudi Pharm. J. 2018, 26, 909–920. [Google Scholar] [CrossRef]
- Gupta, H.; Aqil, M.; Khar, R.K.; Ali, A.; Bhatnagar, A.; Mittal, G. Nanoparticles laden in situ gel for sustained ocular drug delivery. J. Pharm. Bioallied Sci. 2013, 5, 162–165. [Google Scholar] [CrossRef]
- Gupta, H.; Aqil, M.; Khar, R.K.; Ali, A.; Bhatnagar, A.; Mittal, G. Nanoparticles laden in situ gel of levofloxacin for enhanced ocular retention. Drug Deliv. 2013, 20, 306–309. [Google Scholar] [CrossRef] [Green Version]
- Liu, L.; Gao, Q.; Lu, X.; Zhou, H. In situ forming hydrogels based on chitosan for drug delivery and tissue regeneration. Asian J. Pharm. Sci. 2016, 11, 673–683. [Google Scholar] [CrossRef] [Green Version]
- Zhou, H.Y.; Jiang, L.J.; Cao, P.P.; Li, J.B.; Chen, X.G. Glycerophosphate-based chitosan thermosensitive hydrogels and their biomedical applications. Carbohydr. Polym. 2015, 117, 524–536. [Google Scholar] [CrossRef]
- Fabiano, A.; Bizzarri, R.; Zambito, Y. Thermosensitive hydrogel based on chitosan and its derivatives containing medicated nanoparticles for transcorneal administration of 5-fluorouracil. Int. J. Nanomed. 2017, 12, 633–643. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kong, X.; Xu, W.; Zhang, C.; Kong, W. Chitosan temperature-sensitive gel loaded with drug microspheres has excellent effectiveness, biocompatibility and safety as an ophthalmic drug delivery system. Exp. Ther. Med. 2018, 15, 1442–1448. [Google Scholar] [CrossRef]
- Tan, G.; Yu, S.; Li, J.; Pan, W. Development and characterization of nanostructured lipid carriers based chitosan thermosensitive hydrogel for delivery of dexamethasone. Int. J. Biol. Macromol. 2017, 103, 941–947. [Google Scholar] [CrossRef] [PubMed]
- Ahmed, T.A.; Aljaeid, B.M. A potential in situ gel formulation loaded with novel fabricated poly(lactide-co-glycolide) nanoparticles for enhancing and sustaining the ophthalmic delivery of ketoconazole. Int. J. Nanomed. 2017, 12, 1863–1875. [Google Scholar] [CrossRef] [Green Version]
- Schopf, L.; Enlow, E.; Popov, A.; Bourassa, J.; Chen, H. Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation. Ophthalmol. Ther. 2014, 3, 63–72. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, T.; Sall, K.; Holland, E.; Brazzell, R.K.; Coultas, S.; Gupta, P.K. Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery. Clin. Ophthalmol. 2018, 13, 69–86. [Google Scholar] [CrossRef] [Green Version]
- Wentz, S.M.; Price, F.; Harris, A.; Siesky, B.; Ciulla, T. Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery. Expert Opin. Pharmacother. 2019, 20, 1703–1709. [Google Scholar] [CrossRef] [PubMed]
- Steinbach, O.C. Industry update: The latest developments in therapeutic delivery. Ther. Deliv. 2013, 4, 531–535. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Polymer | Drug | Key Results | Ref. |
---|---|---|---|
Polymeric nanoparticles | |||
Galactosylated chitosan | Timolol |
| [43] |
Chitosan | Carteolol |
| [44] |
Chitosan, PCL | Dorzolamide |
| [45] |
Chitosan | Ganciclovir |
| [46] |
Chitosan | Cyclosporin A |
| [47] |
Chitosan | Daptomycin |
| [48] |
Chitosan | Diclofenac |
| [49] |
N-Trimethyl Chitosan | Diclofenac |
| [50] |
Glycol chitosan | Dexamethasone |
| [51] |
Chitosan | Rosmarinic acid |
| [52] |
Chitosan, sodium alginate | Azelastine |
| [53] |
Chitosan, sodium alginate + chitosan coating | 5-fluorouracil |
| [54] |
Chitosan, sodium alginate | Brimonidine |
| [55] |
Chitosan, sodium alginate | Betamethasone sodium phosphate |
| [56] |
Chitosan, sodium alginate | Timolol maleate |
| [57] |
Albumin, chitosan | Atropine sulfate |
| [58] |
Chitosan/PEG | Resveratrol and Quercetin |
| [59] |
Gelatin |
| [60] | |
Gelatin | Moxifloxacin |
| [61] |
Gelatin | Plasmid pMUC5AC |
| [62] |
Eudragit RL 100 | Aceclofenac |
| [63] |
Eudragit RS 100 | Aceclofenac |
| [64] |
Eudragit RL 100 | Acetazolamide |
| [65] |
Eudragit RL 100 | Tacrolimus |
| [66] |
PLGA | Fluorometholone |
| [67] |
PLGA | Aceclofenac |
| [68] |
PLGA | Tacrolimus |
| [69] |
PLGA | Tacrolimus |
| [70] |
PLGA | Pranoprofen |
| [71] |
PLGA | Xanthohumol |
| [72] |
PLGA | Dorzolamide |
| [73] |
PLGA-PEG | Dexibuprofen |
| [74] |
PCL | Celecoxib |
| [75] |
Polymeric micelles | |||
PEG-PCL | Pimecrolimus |
| [76] |
PEG-PLA 3 | Cyclosporine A |
| [77] |
PVCL 4-PVA 5-PEG | Myricetin |
| [78] |
PEG-PLA 3 | Axitinib |
| [79] |
PEG-PCL | Dexamethasone |
| [80] |
PEG-Polylysine | Superoxide dismutase |
| [81] |
Protamine, PEG-b-Polyglutamic acid | Superoxide dismutase |
| [82] |
Tetronic 701,Synperonic PE/F127,Synperonic® PE/P84 | Lornoxicam |
| [83] |
Trademark/Drug Name | Drug Molecule | Clinicaltrials.gov Identifier | Status |
---|---|---|---|
INVELTYS | Loteprednol etabonate | NCT02163824NCT02793817 | FDA 1 approved |
Bromsite | Bromfenac | NCT01576952 | FDA 1 approved |
Dexasite | Dexamethasone | NCT03192137NCT01543490 | Phase III |
OCS-01 | Dexamethasone | NCT04130802 | Phase II |
RX-10045 | Resolvin E1 | NCT02329743 | Phase II |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vaneev, A.; Tikhomirova, V.; Chesnokova, N.; Popova, E.; Beznos, O.; Kost, O.; Klyachko, N. Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye. Int. J. Mol. Sci. 2021, 22, 12368. https://doi.org/10.3390/ijms222212368
Vaneev A, Tikhomirova V, Chesnokova N, Popova E, Beznos O, Kost O, Klyachko N. Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye. International Journal of Molecular Sciences. 2021; 22(22):12368. https://doi.org/10.3390/ijms222212368
Chicago/Turabian StyleVaneev, Alexander, Victoria Tikhomirova, Natalia Chesnokova, Ekaterina Popova, Olga Beznos, Olga Kost, and Natalia Klyachko. 2021. "Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye" International Journal of Molecular Sciences 22, no. 22: 12368. https://doi.org/10.3390/ijms222212368